The drug everyone asks about
$274 semaglutide: what Medicare’s negotiated price does and doesn’t mean for you
Short answer: starting January 1, 2027, Medicare’s negotiated price for the semaglutide family (Ozempic, Rybelsus, and Wegovy) is $274 for a 30-day supply, down 71% from the $959 list price. That is what Medicare pays, not automatically what you pay: your cost still runs through your drug plan’s tiers and phases, and it depends on why the drug was prescribed. Prescribed for diabetes, it flows through normal Part D. Prescribed for weight loss, it runs through a separate $50 a month program instead. Here is how to tell which applies to you and what to check during open enrollment.
Key takeaways
- The negotiated price of $274 per 30-day supply takes effect January 1, 2027, covering Ozempic, Rybelsus, and Wegovy.
- Negotiated price is what Medicare pays; your share depends on your plan’s tier placement and which coverage phase you’re in.
- Diabetes prescriptions run through standard Part D, where the $700 deductible and $2,400 out-of-pocket cap apply.
- Weight-loss prescriptions run through the separate GLP-1 Bridge program at $50 a month, which continues through December 31, 2027.
- Semaglutide is one of 15 drugs getting negotiated prices in January, so plans are re-sorting tiers around them; check yours.
What the negotiated price actually is
Under the Inflation Reduction Act, Medicare negotiates prices directly with manufacturers for a growing list of high-spend drugs. The first ten took effect in 2026. A second group of 15 drugs takes effect January 1, 2027, and semaglutide is the headline: a family of drugs accounting for a large share of the roughly $42.5 billion in 2024 Part D spending covered by this round, used by about 5.3 million people. The negotiated price of $274 for a 30-day supply replaces a $959 list price, a 71% reduction, and applies to Ozempic and Rybelsus (diabetes) and Wegovy (weight management) alike.
What you actually pay at the counter
This is where headlines mislead. The negotiated price sets what Medicare and your plan transact at; your own cost is whatever your plan’s benefit design says for that drug: the deductible first (up to $700 in 2027), then your tier copay or coinsurance, then $0 once your out-of-pocket spending reaches the $2,400 cap. The practical effect of a lower negotiated price is that coinsurance calculated as a percentage falls with it, and you reach the cap having spent less. A lower price is real money for most people taking the drug; it is not a flat $274 bill for everyone.
One tool worth knowing if your costs cluster early in the year: every plan must offer the Medicare Prescription Payment Plan, which spreads your out-of-pocket drug costs into monthly installments across the year rather than charging them all at the pharmacy counter. It doesn’t reduce the total; it stops January from being brutal. Details in the drug cap article.
Why the reason for the prescription changes everything
Medicare treats these drugs differently depending on what they were prescribed to treat, which surprises nearly everyone:
| Prescribed for | How it’s covered | What you pay |
|---|---|---|
| Type 2 diabetes (Ozempic, Rybelsus) | Standard Part D coverage, subject to your plan’s formulary and tiers | Deductible, then tier cost sharing, then $0 after the $2,400 cap |
| Cardiovascular risk reduction with obesity (Wegovy, per its approved indication) | Standard Part D coverage where the plan covers that indication | Same Part D structure as above |
| Weight loss alone | Not standard Part D coverage; runs through the separate GLP-1 Bridge program | $50 per month, outside Part D cost sharing |
The GLP-1 Bridge program runs through December 31, 2027 and covers Wegovy in all forms, Zepbound KwikPen only, and Foundayo.
The distinction is a coverage rule, not a judgment about your health, and it is worth asking your prescriber to document the clinical indication accurately, because that documentation determines which path your prescription takes. The full mechanics of the Bridge program, including which products qualify, are in the GLP-1 Bridge article.
The other 14 drugs
Semaglutide gets the headlines, but the January 1 list also includes Trelegy Ellipta (COPD and asthma), Xtandi (prostate cancer), Pomalyst and Ibrance (blood and breast cancers), Ofev (pulmonary fibrosis), Austedo, and Janumet, with negotiated discounts running from 38% to 85% off list. If you take any of them, the same logic applies: the price Medicare pays falls, your share depends on your plan, and plans are actively re-sorting tiers around the new prices.
What to check this month
- Your ANOC. Look specifically at whether your GLP-1 or other negotiated drug changed tiers for 2027, and whether new restrictions (prior authorization, step therapy, quantity limits) appeared. The five numbers to circle.
- The Plan Finder, from October 15. Enter the drug exactly as prescribed and compare plans on total annual cost; the same drug at the same negotiated price can still cost very differently across plans. Click by click.
- Your indication. If you’re taking it for weight loss and paying Part D prices, or the reverse, that’s worth a conversation with your prescriber and your plan.
- Extra Help. If money is tight, the subsidy cuts drug costs to a few dollars and is widely unclaimed.
Questions people also ask
How much will Ozempic cost on Medicare in 2027?
Does Medicare cover Wegovy for weight loss in 2027?
Is the negotiated price what I pay at the pharmacy?
Which drugs get negotiated Medicare prices in 2027?
Should I switch drug plans because of the negotiated prices?
Sources for this article
- CMS.gov2027 Part D announcement: the negotiated-price round and 2027 program parameters.
- Medicare.govPart D costs: deductible, cap, coverage phases, and the payment plan.
- CMS.gov2027 landscape announcement: plan pricing context for the season.
Figures checked against these sources on September 30, 2026. We update within days when CMS publishes new amounts.
Not sure which path fits you? Get a straight answer.
Start the decoderThe one paid thing
Stop re-reading Medicare articles. Decide, on paper, in two evenings.
The Turning-65 Decision Workbook is this site’s free explanations turned into pages you fill in, so the decision ends up written down instead of rattling around in your head.
- Your enrollment dates calculated from your own birthday, with the penalty deadlines marked
- Advantage vs. Medigap scored against your doctors, drugs, travel, and budget
- Word-for-word scripts for the broker, HR, the pharmacy, and Social Security
- The September re-shop ritual you reuse every fall, with the 2026 and 2027 numbers card
Instant PDF download. Free update when the remaining 2027 figures land. Full refund within 30 days if it doesn’t help, and you keep the PDF.